320
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Efficacy Of Line Probe Assay In Detection Of Drug-Resistant Pulmonary Tuberculosis In Comparison With GeneXpert And Phenotypic Methods In Iran And Genetic Analysis Of Isolates By MIRU-VNTR

, , ORCID Icon, , ORCID Icon, , , ORCID Icon & ORCID Icon show all
Pages 3585-3593 | Published online: 15 Nov 2019

References

  • Yamchi JK, Haeili M, Feyisa SG, et al. Evaluation of efflux pump gene expression among drug susceptible and drug-resistant strains of Mycobacterium tuberculosis from Iran. Infect Genet Evol. 2015;36:23–26. doi:10.1016/j.meegid.2015.08.03626325681
  • Kazemian H, Haeili M, Yamchi JK, et al. Antimycobacterial activity of linezolid against multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis in Iran. Int J Antimicrob Agents. 2015;45:668–670. doi:10.1016/j.ijantimicag.2015.02.00425795315
  • World Health Organization (WHO). Global tuberculosis report 2017. Available from: www.who.int/tb/publications/global_report/ Accessed 1031, 2019.
  • Pourakbari B, Mamishi S, Banar M, Keshtkar AA, Mahmoudi S. Prevalence of TB/HIV co-infection in Iran: a systematic review and meta-analysis. Ann Ig. 2019;31(4):333–348. doi:10.7416/ai.2019.229531268118
  • Kazemian H, Kardan-Yamchi J, Mosavari N, Feizabadi MM. Molecular characterization of multidrug and extensive drug-resistant Mycobacterium tuberculosis isolates from Iran. Infez Med. 2019;27(1):26–31.30882375
  • Nasiri MJ, Dabiri H, Darban-Sarokhalil D, Rezadehbashi M, Zamani S. Prevalence of drug-resistant tuberculosis in Iran: systematic review and meta-analysis. Am J Infect Control. 2014;42(11):1212–1218. doi:10.1016/j.ajic.2014.07.01725242634
  • Kadivar MR, Ghaneh-Shirazi R, Khavandegaran F, Karimi M. Epidemiology of tuberculosis among Afghan immigrants in Fars province, southern Islamic Republic of Iran. East Mediterr Health J. 2007;13(4):758–764.17955756
  • Zignol M, Gemert WV, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ. 2012;90:111–119. doi:10.2471/BLT.11.09258522423162
  • Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoTypeMTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2007;45:2635–2640.17537937
  • Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. EurRespir J. 2011;38:516–528. doi:10.1183/09031936.00073611
  • World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy Statement. 2008;27.
  • World Health Organization. Rapid Implementation of the Xpert® MTB/RIF Diagnostic Test: Technical, Operational ‘'howto' and Practical Considerations. Geneva, Switzerland: WHO; 2011.
  • Jaramillo E. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization; 2008.
  • Ninan MM, Gowri M, Christopher DJ, Rupali P, Michael JS. The diagnostic utility of line probe assays for multidrug-resistant tuberculosis. Pathog Glob Health. 2016;110:194–199. doi:10.1080/20477724.2016.121435027499239
  • Zamani S, Aflaki M, Fooladi AA, et al. MIRU-VNTR analysis of the Mycobacterium tuberculosis isolates from three provinces of Iran. Scand J Infect Dis. 2013;45:124–130. doi:10.3109/00365548.2012.71723322954102
  • Leite CQ, Beretta AL, Anno IS, Telles MA. Standardization of broth microdilution method for Mycobacterium tuberculosis. Mem Inst Oswaldo Cruz. 2000;95:127–129. doi:10.1590/S0074-0276200000010002110656718
  • Kazemian H, Heidari H, Yamchi JK, et al. al. In vitro anti-mycobacterial activity of three medicinal plants of Lamiaceae family. Recent Pat Antiinfect Drug Discov. 2018;26:1–8.
  • Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005–1015. doi:10.1056/NEJMoa090784720825313
  • Van Helden PD, Victor TC, Warren RM, Van Helden EG. Isolation of DNA from Mycobacterium tuberculosis. Methods Mol Med. 2001;54:19–30. doi:10.1385/1-59259-147-7:01921341066
  • Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med. 1994;330:1703–1709. doi:10.1056/NEJM1994061633024027910661
  • Crudu V, Stratan E, Romancenco E, Allerheiligen V, Hillemann A, Moraru N. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as RMP and INH resistances. J Clin Microbiol. 2012;50:1264–1269.22301019
  • Barnard M, van Pittius NG, Van Helden PD, Bosman M, Coetzee G, Warren RM. Diagnostic performance of Genotype® MTBDRplus Version 2 line probe assay is equivalent to the Xpert® MTB/RIF assay. J Clin Microbiol. 2012;50:3712–3716.22972826
  • Hassim S, Shaw PA, Sangweni P, et al. Detection of a substantial rate of multidrug-resistant tuberculosis in an HIV-infected population in South Africa by active monitoring of sputum samples. Clin Infect Dis. 2010;50:1053–1059. doi:10.1086/64951420196651
  • Desikan P, Panwalkar N, Mirza SB, et al. Line probe assay for detection of Mycobacterium tuberculosis complex: an experience from Central India. Indian J Med Res. 2017;145:70–73. doi:10.4103/ijmr.IJMR_831_1428574017
  • Rufai SB, Kumar P, Singh A, Prajapati S, Balooni V, Singh S. Comparison of Xpert MTB/RIF with Line Probe Assay for detection of Rifampicin monoresistant Mycobacterium tuberculosis. J Clin Microbiol. 2014;52:1846–1852.24648554
  • Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low-and high-level resistance. J Clin Microbiol. 2006;44:3659–3664.17021094
  • Varghese B, Shoukri M, Memish Z, et al. Occurrence of Diverse Mutations in Isoniazid- and Rifampicin-Resistant Mycobacterium tuberculosis Isolates from Autochthonous and Immigrant Populations of Saudi Arabia. Microb Drug Resist. 2014;20:623–631. doi:10.1089/mdr.2014.006525014484
  • Muller B, Streicher EM, Hoek KG, et al. inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa? Int J Tuberc Lung Dis. 2011;15:344–351.21333101
  • Shenoy VP, Kumar A, Chawla K. Rapid detection of multidrug-resistant tuberculosis in respiratory specimens at a tertiary care centre in south coastal Karnataka using Genotype MTBDR plus assay. Iran J Microbiol. 2018;10:275–280.30675322
  • Gandhi NR, Brust JC, Moodley P, et al. Minimal diversity of drug-resistant Mycobacterium tuberculosis strains, South Africa. Emerg Infect Dis. 2014;20:426–433. doi:10.3201/eid2003.13108324565645
  • Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011;66:1417–1430. doi:10.1093/jac/dkr17321558086
  • Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother. 2002;46:267–274. doi:10.1128/AAC.46.2.267-274.200211796329
  • Jiao WW, Mokrousov I, Sun GZ, et al. Molecular characteristics of rifampin and isoniazid resistant Mycobacterium tuberculosis strains from Beijing, China. Chin Med J (Engl). 2007;120:814–819. doi:10.1097/00029330-200705010-0001417531124
  • LPA Laboratory Manual. Find diagnostics. 3 2012 [Internet] [cited June 23, 2014] Availablefrom: http://www.finddiagnostics.org/export/sites/default/resourcecentre/reports_brochures/docs/LPA_LaboratoryManual_22Mar2012.pdf Accessed 1031, 2019.
  • Mekonnen D, Admassu A, Mulu W, et al. Multidrug-resistant and heteroresistant Mycobacterium tuberculosis and associated gene mutations in Ethiopia. Int J Infect Dis. 2015;39:34–38. doi:10.1016/j.ijid.2015.06.01326119857